Needham & Company initiates coverage on February IPO Argos Therapeutics (NASDAQ: ARGS) with a Buy rating and $17 price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE